Skip to content

ROBOCOLO study

Safety analysis of robotic right-hemicolectomy for right sided colon cancer

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1032210196
Enrollment
41
Registered
2021-07-14
Start date
2021-08-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition(s) or Problem(s) Studied Colon cancer

Interventions

Robotic right-hemicolectomy

Sponsors

Ishibe Atsushi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients over 20 years old age 2. Histologically, diagnosed with colon cancer 3. Preoperative diagnosis of curative primary resection 4. Main tumor site is cecum (C), ascending colon (A) or right-sided transverse colon (T) and right-hemicolectomy with D2 or higher lymph node dissection is pre-planned 5. Clinical stage I to IIIC (T1-4b, N0-2b, M0: TNM Classification) has been diagnosed 6. Patients who are diagnosed out of the endoscopic resection 7. Patients with tumor maximum diameter of 8 cm or less 8. Patients who do not recognize multiple lesions that require two or more anastomosis places 9. Patients with ECOG Performance Status (PS) score of 0 to 1 10. Patients who have the judgment to fully understand the research content. 11. Patients with written informed consent to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Patients with chemotherapy (systemic anti-cancer drug treatment) and a history of radiation therapy, including treatment for other cancer species. 2. Patients who have a history of open surgery 3. Patients who have a history of laparoscopic stomach resection or colectomy 4. Patients with the latest check values within 14 days before registration meet the following Leukocyte 100 IU / L, ALT> 100 IU / L, Serum Cr> 1.5 mg / dl. 5. Other patients who are judged to be unsuitable as a subject by the doctor's judgment.

Design outcomes

Primary

MeasureTime frame
Postoperative complications within 30 days after surgery

Secondary

MeasureTime frame
1. Conversion rate 2. Readmission rate within 30 days after surgery 3. Mortality rate within 30 days after surgery 4. Intraoperative adverse events (vascular damage / organ damage / reconstruction / other) 5. Postoperative recovery (postoperative hospital stay, time to first flatus, time to first oral intake) 6. Surgical results (blood loss, operative time, console time, harvested lymph node number, R0 resection rate)

Contacts

Public ContactJun Watanabe

Yokohama City University Medical Center

jun0926@yokohama-cu.ac.jp+81-45-261-5656

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026